Stronger Suppression of Serum Testosterone and FSH Levels by a Synthetic Estrogen than by Castration or an LH-RH Agonist

Serum levels of LH, FSH and testosterone(T)were measured by radioimmunoassays in 36 patients with advanced prostate cancer before and during androgen ablation therapies. Both leuprolide acetate(LH-RH agonist：LHRH-A)and diethylstilbestrol diphosphate(DES-DP)administration decreased serum LH significa...

Full description

Saved in:
Bibliographic Details
Published in:ENDOCRINE JOURNAL 1997, Vol.44 (4), p.527-532
Main Authors: SATOSHI KITAHARA, KEN-ICHIRO YOSHIDA, KAZUHIRO ISHIZAKA, YUKIO KAGEYAMA, SATORU KAWAKAMI, TOSHIHIKO TSUJII, HIROYUKI OSHIMA
Format: Article
Language:Japanese
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 532
container_issue 4
container_start_page 527
container_title ENDOCRINE JOURNAL
container_volume 44
creator SATOSHI KITAHARA
KEN-ICHIRO YOSHIDA
KAZUHIRO ISHIZAKA
YUKIO KAGEYAMA
SATORU KAWAKAMI
TOSHIHIKO TSUJII
HIROYUKI OSHIMA
description Serum levels of LH, FSH and testosterone(T)were measured by radioimmunoassays in 36 patients with advanced prostate cancer before and during androgen ablation therapies. Both leuprolide acetate(LH-RH agonist：LHRH-A)and diethylstilbestrol diphosphate(DES-DP)administration decreased serum LH significantly to an undetectable level(LHRH-A：P
format article
fullrecord <record><control><sourceid>medicalonline</sourceid><recordid>TN_cdi_medicalonline_journals_cq6endoc_1997_004404_010_0527_05321085144</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>cq6endoc_1997_004404_010_0527_05321085144</sourcerecordid><originalsourceid>FETCH-LOGICAL-m1080-77641252913f439b1604fc513b9ddb4d39851bd3f6a02071d07199e0351836953</originalsourceid><addsrcrecordid>eNotjttqwzAMhnOxwUrXd9ALBORTEl-W0sMgMFi66-DESpuR2l3sju3t5x0uhND_6_-ku2yBmlV5pZV-yFYhjB1yrkpeKL7IPps4e3eiGZrb9TpTsr0DP0BD8-0CRwrRh0hph8A4C7vmADV90BSg-wIDzZeLZ4pjD9uQSCdyEM_G_ZgbkxQTf3lzCkN9yF8OsD55N4b4mN0PZgq0-u_L7HW3PW4Oef28f9qs6_zCsMK8LAvJuOKaiUEK3bEC5dArJjptbSet0JVinRVDYZBjyWwqrQmFYpUotBLLbP_HvZAdezN5N42O2jd_m1262_bvBTnr-zbFyhZRSpQtMmxR8TQrwdMfikkpvgFLbWFQ</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Stronger Suppression of Serum Testosterone and FSH Levels by a Synthetic Estrogen than by Castration or an LH-RH Agonist</title><source>J-STAGE (Japan Science &amp; Technology Information Aggregator, Electronic) - Open Access English articles</source><creator>SATOSHI KITAHARA ; KEN-ICHIRO YOSHIDA ; KAZUHIRO ISHIZAKA ; YUKIO KAGEYAMA ; SATORU KAWAKAMI ; TOSHIHIKO TSUJII ; HIROYUKI OSHIMA</creator><creatorcontrib>SATOSHI KITAHARA ; KEN-ICHIRO YOSHIDA ; KAZUHIRO ISHIZAKA ; YUKIO KAGEYAMA ; SATORU KAWAKAMI ; TOSHIHIKO TSUJII ; HIROYUKI OSHIMA ; Tokyo Medical and Dental University School of Medicine ; Department of Urology ; Dokkyo University School of Medicine ; Department og Urology</creatorcontrib><description><![CDATA[Serum levels of LH, FSH and testosterone(T)were measured by radioimmunoassays in 36 patients with advanced prostate cancer before and during androgen ablation therapies. Both leuprolide acetate(LH-RH agonist：LHRH-A)and diethylstilbestrol diphosphate(DES-DP)administration decreased serum LH significantly to an undetectable level(LHRH-A：P<0.01, DES-DP：P<0.05). LHRH-A and DES-DP diminished serum FSH to 20% of the pre-treatment level(P<0.005)and to an undetectable level(P<0.001), respectively. LHRH-A and DES-DP decreased serum T to the castration level and an undetectable level, respectively(P<0.001). Serum levels of the same 3 hormones before and after DES-DP administration were measured in 8 patients who received DES-DP after LHRH-A treatment or castration because of relapse of the disease. DES-DP lowered serum FSH further than LHRH-A to an undetectable level(P<0.005)and diminished T further than previous treatments to an undetectable level(P<0.05 vs. LHRH-A, P<0.01 vs. castration). These results suggest that 1)DES-DP is able to reduce T production from extra-testicular site(s), and achieve the minimal serum T level, and 2)this DES-DP action appears to be one of the mechanisms of the effectiveness of estrogen on refractory prostate cancer after castration or LHRH-A. In addition, basal(independent of LH-RH)FSH secretion in elderly men is about 20% of total FSH secretion and DES-DP inhibits the basal FSH secretion at the level of the pituitary.]]></description><identifier>ISSN: 0918-8959</identifier><language>jpn</language><publisher>The Japan Endocrine Society</publisher><ispartof>ENDOCRINE JOURNAL, 1997, Vol.44 (4), p.527-532</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4010</link.rule.ids></links><search><creatorcontrib>SATOSHI KITAHARA</creatorcontrib><creatorcontrib>KEN-ICHIRO YOSHIDA</creatorcontrib><creatorcontrib>KAZUHIRO ISHIZAKA</creatorcontrib><creatorcontrib>YUKIO KAGEYAMA</creatorcontrib><creatorcontrib>SATORU KAWAKAMI</creatorcontrib><creatorcontrib>TOSHIHIKO TSUJII</creatorcontrib><creatorcontrib>HIROYUKI OSHIMA</creatorcontrib><creatorcontrib>Tokyo Medical and Dental University School of Medicine</creatorcontrib><creatorcontrib>Department of Urology</creatorcontrib><creatorcontrib>Dokkyo University School of Medicine</creatorcontrib><creatorcontrib>Department og Urology</creatorcontrib><title>Stronger Suppression of Serum Testosterone and FSH Levels by a Synthetic Estrogen than by Castration or an LH-RH Agonist</title><title>ENDOCRINE JOURNAL</title><description><![CDATA[Serum levels of LH, FSH and testosterone(T)were measured by radioimmunoassays in 36 patients with advanced prostate cancer before and during androgen ablation therapies. Both leuprolide acetate(LH-RH agonist：LHRH-A)and diethylstilbestrol diphosphate(DES-DP)administration decreased serum LH significantly to an undetectable level(LHRH-A：P<0.01, DES-DP：P<0.05). LHRH-A and DES-DP diminished serum FSH to 20% of the pre-treatment level(P<0.005)and to an undetectable level(P<0.001), respectively. LHRH-A and DES-DP decreased serum T to the castration level and an undetectable level, respectively(P<0.001). Serum levels of the same 3 hormones before and after DES-DP administration were measured in 8 patients who received DES-DP after LHRH-A treatment or castration because of relapse of the disease. DES-DP lowered serum FSH further than LHRH-A to an undetectable level(P<0.005)and diminished T further than previous treatments to an undetectable level(P<0.05 vs. LHRH-A, P<0.01 vs. castration). These results suggest that 1)DES-DP is able to reduce T production from extra-testicular site(s), and achieve the minimal serum T level, and 2)this DES-DP action appears to be one of the mechanisms of the effectiveness of estrogen on refractory prostate cancer after castration or LHRH-A. In addition, basal(independent of LH-RH)FSH secretion in elderly men is about 20% of total FSH secretion and DES-DP inhibits the basal FSH secretion at the level of the pituitary.]]></description><issn>0918-8959</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNotjttqwzAMhnOxwUrXd9ALBORTEl-W0sMgMFi66-DESpuR2l3sju3t5x0uhND_6_-ku2yBmlV5pZV-yFYhjB1yrkpeKL7IPps4e3eiGZrb9TpTsr0DP0BD8-0CRwrRh0hph8A4C7vmADV90BSg-wIDzZeLZ4pjD9uQSCdyEM_G_ZgbkxQTf3lzCkN9yF8OsD55N4b4mN0PZgq0-u_L7HW3PW4Oef28f9qs6_zCsMK8LAvJuOKaiUEK3bEC5dArJjptbSet0JVinRVDYZBjyWwqrQmFYpUotBLLbP_HvZAdezN5N42O2jd_m1262_bvBTnr-zbFyhZRSpQtMmxR8TQrwdMfikkpvgFLbWFQ</recordid><startdate>1997</startdate><enddate>1997</enddate><creator>SATOSHI KITAHARA</creator><creator>KEN-ICHIRO YOSHIDA</creator><creator>KAZUHIRO ISHIZAKA</creator><creator>YUKIO KAGEYAMA</creator><creator>SATORU KAWAKAMI</creator><creator>TOSHIHIKO TSUJII</creator><creator>HIROYUKI OSHIMA</creator><general>The Japan Endocrine Society</general><scope/></search><sort><creationdate>1997</creationdate><title>Stronger Suppression of Serum Testosterone and FSH Levels by a Synthetic Estrogen than by Castration or an LH-RH Agonist</title><author>SATOSHI KITAHARA ; KEN-ICHIRO YOSHIDA ; KAZUHIRO ISHIZAKA ; YUKIO KAGEYAMA ; SATORU KAWAKAMI ; TOSHIHIKO TSUJII ; HIROYUKI OSHIMA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-m1080-77641252913f439b1604fc513b9ddb4d39851bd3f6a02071d07199e0351836953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>jpn</language><creationdate>1997</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SATOSHI KITAHARA</creatorcontrib><creatorcontrib>KEN-ICHIRO YOSHIDA</creatorcontrib><creatorcontrib>KAZUHIRO ISHIZAKA</creatorcontrib><creatorcontrib>YUKIO KAGEYAMA</creatorcontrib><creatorcontrib>SATORU KAWAKAMI</creatorcontrib><creatorcontrib>TOSHIHIKO TSUJII</creatorcontrib><creatorcontrib>HIROYUKI OSHIMA</creatorcontrib><creatorcontrib>Tokyo Medical and Dental University School of Medicine</creatorcontrib><creatorcontrib>Department of Urology</creatorcontrib><creatorcontrib>Dokkyo University School of Medicine</creatorcontrib><creatorcontrib>Department og Urology</creatorcontrib><jtitle>ENDOCRINE JOURNAL</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SATOSHI KITAHARA</au><au>KEN-ICHIRO YOSHIDA</au><au>KAZUHIRO ISHIZAKA</au><au>YUKIO KAGEYAMA</au><au>SATORU KAWAKAMI</au><au>TOSHIHIKO TSUJII</au><au>HIROYUKI OSHIMA</au><aucorp>Tokyo Medical and Dental University School of Medicine</aucorp><aucorp>Department of Urology</aucorp><aucorp>Dokkyo University School of Medicine</aucorp><aucorp>Department og Urology</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Stronger Suppression of Serum Testosterone and FSH Levels by a Synthetic Estrogen than by Castration or an LH-RH Agonist</atitle><jtitle>ENDOCRINE JOURNAL</jtitle><date>1997</date><risdate>1997</risdate><volume>44</volume><issue>4</issue><spage>527</spage><epage>532</epage><pages>527-532</pages><issn>0918-8959</issn><abstract><![CDATA[Serum levels of LH, FSH and testosterone(T)were measured by radioimmunoassays in 36 patients with advanced prostate cancer before and during androgen ablation therapies. Both leuprolide acetate(LH-RH agonist：LHRH-A)and diethylstilbestrol diphosphate(DES-DP)administration decreased serum LH significantly to an undetectable level(LHRH-A：P<0.01, DES-DP：P<0.05). LHRH-A and DES-DP diminished serum FSH to 20% of the pre-treatment level(P<0.005)and to an undetectable level(P<0.001), respectively. LHRH-A and DES-DP decreased serum T to the castration level and an undetectable level, respectively(P<0.001). Serum levels of the same 3 hormones before and after DES-DP administration were measured in 8 patients who received DES-DP after LHRH-A treatment or castration because of relapse of the disease. DES-DP lowered serum FSH further than LHRH-A to an undetectable level(P<0.005)and diminished T further than previous treatments to an undetectable level(P<0.05 vs. LHRH-A, P<0.01 vs. castration). These results suggest that 1)DES-DP is able to reduce T production from extra-testicular site(s), and achieve the minimal serum T level, and 2)this DES-DP action appears to be one of the mechanisms of the effectiveness of estrogen on refractory prostate cancer after castration or LHRH-A. In addition, basal(independent of LH-RH)FSH secretion in elderly men is about 20% of total FSH secretion and DES-DP inhibits the basal FSH secretion at the level of the pituitary.]]></abstract><pub>The Japan Endocrine Society</pub><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0918-8959
ispartof ENDOCRINE JOURNAL, 1997, Vol.44 (4), p.527-532
issn 0918-8959
language jpn
recordid cdi_medicalonline_journals_cq6endoc_1997_004404_010_0527_05321085144
source J-STAGE (Japan Science & Technology Information Aggregator, Electronic) - Open Access English articles
title Stronger Suppression of Serum Testosterone and FSH Levels by a Synthetic Estrogen than by Castration or an LH-RH Agonist
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-24T07%3A37%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-medicalonline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Stronger%20Suppression%20of%20Serum%20Testosterone%20and%20FSH%20Levels%20by%20a%20Synthetic%20Estrogen%20than%20by%20Castration%20or%20an%20LH-RH%20Agonist&rft.jtitle=ENDOCRINE%20JOURNAL&rft.au=SATOSHI%20KITAHARA&rft.aucorp=Tokyo%20Medical%20and%20Dental%20University%20School%20of%20Medicine&rft.date=1997&rft.volume=44&rft.issue=4&rft.spage=527&rft.epage=532&rft.pages=527-532&rft.issn=0918-8959&rft_id=info:doi/&rft_dat=%3Cmedicalonline%3Ecq6endoc_1997_004404_010_0527_05321085144%3C/medicalonline%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-m1080-77641252913f439b1604fc513b9ddb4d39851bd3f6a02071d07199e0351836953%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true